We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
(+27%)
Cap. Flow
+$9.92M
Cap. Flow
% of AUM
0.69%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9
quarters
Top 10 Avg Time Held Equity + Options
4.7
quarters
Top 20 Avg Time Held Equity + Options
4.1
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.7
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXTM
NxStage Medical Inc.
NXTM
|
+$24.7M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$23.8M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$18.4M |
| 4 |
STJ
St Jude Medical
STJ
|
+$16.6M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$41.5M |
| 2 |
Humana
HUM
|
+$20.1M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$12.4M |
| 4 |
Baxter International
BAX
|
+$9.04M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$6.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.68% |
| 2 | Miscellaneous | 20.64% |
| 3 | Consumer Staples | 0.52% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
LCI
101
DELISTED
Lannett Company, Inc.
LCI
| $634K | 0.04% |
+6,668
| New | +$571K |
2016 Q2
0 quarters
|
|
|
MGLN
102
DELISTED
Magellan Health Services, Inc.
MGLN
| $577K | 0.04% |
8,772
| – | – |
2015 Q1
5 quarters
|
|
103
DELISTED
Alpine Immune Sciences Inc
ALPN
| $575K | 0.04% |
31,250
| – | – |
2015 Q3
3 quarters
|
|
104
McKesson
MCK
$111B
| $556K | 0.04% |
2,979
-209
| -7% | -$36.7K |
2015 Q4
2 quarters
|
|
|
AET
105
DELISTED
Aetna Inc
AET
| $544K | 0.04% |
+4,454
| New | +$511K |
2016 Q2
0 quarters
|
|
|
WCG
106
DELISTED
Wellcare Health Plans, Inc.
WCG
| $542K | 0.04% |
5,056
-392
| -7% | -$38.3K |
2016 Q1
1 quarter
|
|
|
VWR
107
DELISTED
VWR Corporation
VWR
| $539K | 0.04% |
18,657
| – | – |
2016 Q1
1 quarter
|
|
108
AMN Healthcare
AMN
$1.41B
| $537K | 0.04% |
13,445
-3,983
| -23% | -$147K |
2016 Q1
1 quarter
|
|
109
DELISTED
VCA Inc.
WOOF
| $537K | 0.04% |
+7,940
| New | +$504K |
2016 Q2
0 quarters
|
|
110
Universal Health Services
UHS
$10.5B
| $535K | 0.04% |
3,989
| – | – |
2016 Q1
1 quarter
|
|
|
STML
111
DELISTED
Stemline Therapeutics, Inc.
STML
| $532K | 0.04% |
78,603
| – | – |
2015 Q1
5 quarters
|
|
112
Labcorp
LH
$25.6B
| $520K | 0.04% |
+4,644
| New | +$500K |
2016 Q2
0 quarters
|
|
113
Cencora
COR
$62B
| $516K | 0.04% |
+6,500
| New | +$521K |
2016 Q2
0 quarters
|
|
114
Spyre Therapeutics
SYRE
$8.03B
| $515K | 0.04% |
+4,236
| New | +$812K |
2016 Q2
0 quarters
|
|
|
IMMU
115
DELISTED
Immunomedics Inc
IMMU
| $514K | 0.04% |
221,700
-1,198,300
| -84% | -$4M |
2015 Q4
2 quarters
|
|
|
AFAM
116
DELISTED
Almost Family Inc
AFAM
| $509K | 0.04% |
11,942
-1,133
| -9% | -$46.7K |
2015 Q4
2 quarters
|
|
117
United Therapeutics
UTHR
$23.6B
| $503K | 0.03% |
4,753
-15,247
| -76% | -$1.7M |
2016 Q1
1 quarter
|
|
118
Cardinal Health
CAH
$55.1B
| $499K | 0.03% |
6,398
+451
| +8% | +$36K |
2016 Q1
1 quarter
|
|
119
DELISTED
Cogentix Medical, Inc.
CGNT
| $498K | 0.03% |
517,760
-155,497
| -23% | -$153K |
2015 Q2
4 quarters
|
|
120
HCA Healthcare
HCA
$99.3B
| $478K | 0.03% |
6,202
-984
| -14% | -$77.7K |
2016 Q1
1 quarter
|
|
|
KND
121
DELISTED
Kindred Healthcare
KND
| $478K | 0.03% |
+42,301
| New | +$530K |
2016 Q2
0 quarters
|
|
122
Molina Healthcare
MOH
$10.7B
| $459K | 0.03% |
9,200
+1,148
| +14% | +$61.4K |
2015 Q2
4 quarters
|
|
123
UnitedHealth
UNH
$340B
| $456K | 0.03% |
3,231
-1,115
| -26% | -$149K |
2015 Q4
2 quarters
|
|
124
Phibro Animal Health
PAHC
$1.52B
| $453K | 0.03% |
+24,300
| New | +$507K |
2016 Q2
0 quarters
|
|
125
Charles River Laboratories
CRL
$14.4B
| $452K | 0.03% |
5,482
-762
| -12% | -$62.8K |
2015 Q4
2 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2016 Portfolio in Review
As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
- Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
- Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
- Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
- Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
- Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
- Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.
Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.